86 related articles for article (PubMed ID: 38630291)
1. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.
Hanssens H; Meeus F; Gesquiere EL; Puttemans J; De Vlaeminck Y; De Veirman K; Breckpot K; Devoogdt N
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891821
[TBL] [Abstract][Full Text] [Related]
2. IL-18-secreting multi-antigen targeting CAR T-cells eliminate antigen-low myeloma in an immunocompetent mouse model.
Ng BD; Rajagopalan A; Kousa AI; Fischman JS; Chen S; Massa AR; Elias HK; Manuele D; Galiano M; Lemarquis AL; Boardman AP; DeWolf S; Pierce JA; Bogen B; James SE; van den Brink MRM
Blood; 2024 Apr; ():. PubMed ID: 38579288
[TBL] [Abstract][Full Text] [Related]
3. Anti-BCMA-engineered Exosomes for Bortezomib Targeted Delivery in Multiple Myeloma.
Yuan S; Li Q; He C; Bing M; Zhang X; Xu H; Wang Z; Zhao M; Zhang Y; Chai Y; Li B; Zhuang W
Blood Adv; 2024 Jun; ():. PubMed ID: 38875465
[TBL] [Abstract][Full Text] [Related]
4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
5. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
Front Immunol; 2022; 13():991092. PubMed ID: 36119032
[TBL] [Abstract][Full Text] [Related]
6. Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.
Stock S; Fertig L; Gottschlich A; Dörr J; Märkl F; Majed L; Menkhoff VD; Grünmeier R; Rejeski K; Cordas Dos Santos DM; Theurich S; von Bergwelt-Baildon M; Endres S; Subklewe M; Kobold S
Cancer Immunol Immunother; 2024 Apr; 73(6):100. PubMed ID: 38630291
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
[TBL] [Abstract][Full Text] [Related]
9. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
10. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
11. Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro.
Moazzeni A; Kheirandish M; Khamisipour G; Rahbarizadeh F
Immunobiology; 2023 May; 228(3):152376. PubMed ID: 37058845
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control.
Stock S; Klüver AK; Fertig L; Menkhoff VD; Subklewe M; Endres S; Kobold S
Int J Cancer; 2023 Nov; 153(10):1706-1725. PubMed ID: 37350095
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma.
Rejeski K; Jain MD; Smith EL
Transplant Cell Ther; 2023 Jul; 29(7):418-428. PubMed ID: 37076102
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes following CAR T cell therapy: what we know so far.
Cappell KM; Kochenderfer JN
Nat Rev Clin Oncol; 2023 Jun; 20(6):359-371. PubMed ID: 37055515
[TBL] [Abstract][Full Text] [Related]
15. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Gottschlich A; Thomas M; Grünmeier R; Lesch S; Rohrbacher L; Igl V; Briukhovetska D; Benmebarek MR; Vick B; Dede S; Müller K; Xu T; Dhoqina D; Märkl F; Robinson S; Sendelhofert A; Schulz H; Umut Ö; Kavaka V; Tsiverioti CA; Carlini E; Nandi S; Strzalkowski T; Lorenzini T; Stock S; Müller PJ; Dörr J; Seifert M; Cadilha BL; Brabenec R; Röder N; Rataj F; Nüesch M; Modemann F; Wellbrock J; Fiedler W; Kellner C; Beltrán E; Herold T; Paquet D; Jeremias I; von Baumgarten L; Endres S; Subklewe M; Marr C; Kobold S
Nat Biotechnol; 2023 Nov; 41(11):1618-1632. PubMed ID: 36914885
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
